Professor Thompson G Robinson BMedSci MD FRCP FESO AFHEA

Professor Thompson G Robinson

Personal details

  • Pro Vice-Chancellor, Head of the College of Life Sciences and Dean of Medicine
  • Professor of Stroke Medicine
  • +44 (0)116 252 2965


  • For University-related enquiries, please email Carrie Laverick (PA) on or call +44 (0)116 252 2965
  • For NHS enquiries, email Jennifer Kerry (PA) on or call +44 (0)116 252 3182
  • For NIHR Enquiries, email Janette Moore on or call +44 (0)116 252 5814


I undertook my medical training in Nottingham, Newcastle-Upon-Tyne and Leicester, and was appointed Pro Vice-Chancellor, Head of the College of Life Sciences and Dean of Medicine in April 2021. I am also Professor of Stroke Medicine at the University of Leicester, and Honorary Consultant Physician in Stroke Medicine for University Hospitals of Leicester NHS Trust. I was appointed an NIHR Senior Investigator in April 2016.

My other responsibilities include: Past President of the British Association of Stroke Physicians, and National Specialty Lead for Stroke for the NIHR Clinical Research Network.

My research interests include clinical trials in acute stroke, particularly blood pressure and thrombolysis management, and studies of cardiovascular and cerebrovascular regulatory mechanisms



  • Bachelor of Medical Sciences (University of Nottingham, 1985)
  • Bachelor of Medicine (University of Nottingham, 1987)
  • Bachelor of Surgery (University of Nottingham, 1987)
  • Membership (Royal College of Physicians, 1990)
  • Specialist Register: General Internal Medicine (General Medical Council, 1996)
  • Specialist Register: Geriatric Medicine (General Medical Council, 1996)
  • Doctor of Medicine (University of Leicester, 1998)
  • Fellowship (Royal College of Physicians of London, 2002)
  • Fellowship (European Stroke Organisation, 2012)
  • Associate Fellowship (Higher Education Academy, 2017)


Current Research

My main research focus is acute stroke blood pressure; investigating the pathophysiology of BP changes following stroke, changes in cerebrovascular autoregulation and the prognosis of these variables.  This has culminated in the leadership and/ or national co-ordination of acute stroke trials (CHHIPS, COSSACS, ENCHANTED BP, ENCHANTED Dose, INTERACT2) that have informed US, European and UK guidelines for the management of this common acute stroke management problem. In addition, my research is at the forefront of the development of non-invasive assessments of cerebral autoregulation, demonstrating impaired autoregulation in the acute stroke period, as well as refining methods of cerebral autoregulation assessment.


My current research funding as Principal or Co-Applicant:

  1. Australian National Health and Medical Research Council (via The Florey Institute, Melbourne, Australia) 2020 (3 years, Principal Applicant); A Very Early Rehabilitation Trial – Dose (AVERT-DOSE) (£512,998)
  2. National Institute for Health Research Health Technology Assessment Programme 2020 (5 years, Co-Applicant); Tranexamic acid in IntraCerebral Haemorrhage trial – 3 (TICH-3) (£4,464,044)
  3. British Heart Foundation 2019 (4 years, Co-applicant); Multicentre, prospective randomised open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care in the prevention of disability at 3 months in minor ischaemic stroke with proven acute symptomatic occlusion (TEMPO-2) (£488,647)
  4. British Heart Foundation 2019 (5 years, Co-applicant); BHF Accelerator Award (£1,000,000)
  5. British Heart Foundation 2018 (3 years, Principal Applicant); Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST) (£323,014)
  6. Dunhill Medical Trust 2018 (3 years, Co-applicant); The cognition and flow study: The effects of brain training on brain blood flow (£297,289)
  7. Canadian Institutes of Health Research 2018 (5 years, Co-applicant); TEMPO-2 – A randomised controlled trial of TNK-tPA versus standard of care for minor ischemic stroke with proven occlusion. (CAN$1,992,825)
  8. Stroke Association 2018 (2 years, Co-applicant); Early versus late initiation of direct oral anticoagulants in post-ischaemic stroke patients with atrial fibrillation (£133,953)
  9. Stroke Association/ British Heart Foundation/ Alzheimer’s Society 2017 (5 years, Co-applicant); Rates, Risks and Routes to Reduce Vascular Dementia (R4VaD) (£1,179,476)
  10. 10. British Heart Foundation 2016 (5 years, Principal Applicant); Leicester Cardiovascular Genomics Group (£573,768)
  11. NIHR Clinical Research Network 2015 (6 years, Principal Applicant); National Specialty Lead for Stroke (£120,000)
  12. Stroke Association 2015 (4 years, Co-applicant); Prevention Of Hypertensive Injury to the Brain by Intensive Treatment after IntraCerebral Haemorrhage: a pilot randomised trial of home telemetry-guided treatment (PROHIBIT-ICH) (£448,144)
  13. Australian National Health and Medical Research Council 2015 (5 years, Co-applicant); Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) (AU$5,311,291)


Awards and Nominations

NIHR Senior Investigator (2016)


Current External Roles

  • Associate Non-Executive Director, Northampton General Hospital NHS Trust (2019 to date)
  • Past President, British Association of Stroke Physicians (2020 to date)
  • External Advisor (Geriatric Medicine), National Audit of Breast Cancer in Older Persons, Royal College of Surgeons of England (2016 to date)
  • National Specialty Lead for Stroke, NIHR Clinical Research Network (2015 to date)
  • Trustee, Stroke Association (2014 to date)


Editorial Board and Reviewer Experience

  • Associate Editor, Cerebrovascular Diseases, 2020 to date
  • Supplements Editor, Age and Ageing (2003 to 2016)
  • Associate Editor (Stroke and Neurology), Age and Ageing (2003 to 2016)
  • Journal reviewer, including Lancet, Lancet Neurology, Neurology, Circulation, Hypertension, Stroke.
  • Grant reviewer, including network review panel member in Canada (Institute of Circulatory and Respiratory Health, 2019), France (Agence Nationale de la Recherche, 2018) and the USA (National Institute of Health, 2015 and 2018)


Periodic Reviewer and External Examiner Experience

  • University of Birmingham (Doctor of Medicine Thesis)
  • University of Edinburgh (Doctor of Medicine Thesis)
  • University of Leeds (Doctor of Philosophy Thesis)
  • University of London (Doctor of Medicine Theses & Doctor of Philosophy Theses)
  • University of Nottingham (Doctor of Science, Doctor of Medicine & Doctor of Philosophy Theses)
  • University of Oxford (Doctor of Philosophy Thesis)
  • University of Sheffield (Doctor of Philosophy Thesis)
  • University of East Anglia (External Examiner, Year 3 Modules, 2011 to 2016)
  • University of Leeds (Doctor of Philosophy Thesis)
  • University of Leicester:
    • Doctor of Medicine Theses
    • Doctor of Philosophy Theses
    • Master of Science Thesis
    • Bachelor of Science Theses
    • Leicester Medical School (Clinical Examiner)


Research Supervision

I have supervised fifteen higher degree research students to completion (PhD 7, MD 8), and am supervising the following current projects:

  • Doctor of Medicine: Maternal haemodynamic changes during pregnancy among pregnant women on metformin.
  • Doctor of Philosophy: Assessment of cerebral autoregulation and cerebral haemodynamics in clinical applications


Key Publications

>300 original publications; 10171 citations; Google Scholar H-index 54, i10-index 171 (at 09 Apr 2021);

For Full List:

Orcid ID: 0000-0003-2144-2468

Google Scholar Link:

Selected Publications

  1. Anderson CS, Huang Y, Lindley RI, Chen X, Arima H, Chen G, Li Q, Billot L, Delcourt C, Bath PM, Broderick JP, Demchuk AM, Donnan GA, Durham AC, Lavados PM, Lee TH, Levi C, Martins SO, Olavarria VV, Pandian JD, Parsons MW, Pontes-Neto OM, Ricci S, Sato S, Sharma VK, Silva F, Song L, Thang NH, Wardlaw JM, Wang JG, Wang X, Woodward M, Chalmers J, Robinson TG. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international randomised, open-label, blinded-endpoint phase 3 trial. Lancet 2019; 393: 877-888. doi: 10.1016/s0140-6736(19)30038-8. PubMed: PMID30739745.
  2. Bath PM, Scutt P, Anderson CS, Ankolekar S, Appleton JP, Berge E, Cala L, Dixon M, England TJ, Godolphin PJ, Havard D, Haywood L, Hepburn T, Krishnan K, Mair G, Montgomery AA, Muir K, Phillips SJ, Pocock S, Potter J, Price CI, Randall M, Robinson TG, Roffe C, Rothwell PM, Sandset EC, Sanossian N, Saver JL, Shone A, Siriwardena AN, Wardlaw JM, Woodhouse LJ, Venables G, Sprigg N. Pre-hospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): a randomised, sham-controlled, blinded, phase III, superiority ambulance-based trial. Lancet 2019; 393: 1009-1020. doi: 10.1016/s0140-6736(19)30194-1. PubMed: PMID30738649.
  3. Sprigg N, Flaherty K, Appleton JP, Al-Shahi Salman R, Bereczki D, Beridze M, Christensen H, Ciccone A, Collins R, Czlonkowska A, Dineen RA, Duley L, Egea-Guerrero JJ, England TJ, Krishnan K, Laska AC, Law ZK, Ozturk S, Pocock SJ, Roberts I, Robinson TG, Roffe C, Seiffge D, Scutt P, Thanabalan J, Werring D, Whynes D, Bath PM, for the TICH-2 Investigators. Tranexamic acid for hyperacute primary intracerebral haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet 2018; 391: 2107-2115. doi: 10.1016/s0140-6736(18)31033-x. PubMed: PMID29778325.
  4. Bath PM, Woodhouse LJ, Appleton JP, Beridze M, Christensen H, Dineen RA, Duley L, England TJ, Flaherty K, Havard D, Heptinstall S, James M, Krishnan K, Markus HS, Montgomery GS, Pocock SJ, Randall M, Ranta A, Robinson TG, Scutt P, Venables GS, Sprigg N. Intensive versus guideline antiplatelet therapy in patients with acute cerebral ischaemic (TARDIS): a randomised, open-label, phase III, superiority trial. Lancet 2018; 391: 850-859. doi: 10.1016/s0140-6736(17)32849-0. PubMed: PMID29274727.
  5. Anderson CS, Arima H, Lavados P, Billot L, Hackett ML, Olavarria VV, Venturelli PM, Brunser A, Peng B, Cui L, Song L, Rogers K, Middleton S, Lim JY, Forshaw D, Lightbody CE, Woodward M, Pontes-Neto O, De Silva HA, Lin R-T, Lee T-H, Pandian JD, Mead GE, Robinson T, Watkins C. Cluster-randomized, crossover trial of head positioning in acute stroke. New England Journal of Medicine 2017; 376: 2437-2447. doi: 10.1056/nejmoa1615715. PubMed: PMID28636854.
  6. Anderson CS, Robinson T, Lindley RI, Arima H, Lavados P, Lee T-H, Broderick JP, Chen X, Chen G, Sharma VK, Kim JS, Thang NH, Cao Y, Parsons MW, Levi C, Huang Y, Olavarria V, Demchuck A, Bath PMW, Donnan GA, Martins S, Pontes-Neto OM, Silva F, Ricci S, Billot L, Woodward M, Li Q, Wang JG, Chalmers J. Trial of low-dose versus standard-dose intravenous alteplase in patients with acute ischemic stroke. New England Journal of Medicine 2016; 374: 2313-2323. doi: 10.1056/NEJMoa1515510.  PubMed: PMID27161018.
  7. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J; the INTERACT2 Investigators. Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage. New England Journal of Medicine 2013; 368: 2355-65. doi: 10.1056/nejmoa1214609. PubMed: PMID23713578.
  8. Potter JF, Robinson TG, Ford GA, Mistri A, James M, Chernova J, Jagger C. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS): A Randomised, Placebo-controlled, Double-blind Pilot Trial. Lancet Neurology 2009; 8: 48-56. doi: 10.1016/s1474-4422(08)70263-1. PubMed: PMID19058760.
  9. Robinson TG, Potter JF, Ford GA, Bulpitt CJ, Chernova J, Jagger C, James MA, Knight J, Markus HS, Mistri AK,  Poulter NR.  Effects of antihypertensive treatment after stroke in the Continue Or Stop post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurology 2010; 9: 767-75. doi: 10.1016/s1474-4422(10)70163-0. PubMed: PMID20621562.
  10. Robinson TG, Dawson SL, Eames PJ, Panerai RB, Potter JF. Cardiac Baroreceptor Sensitivity Predicts Long-Term Outcome After Acute Ischemic Stroke. Stroke 2003; 34: 705-12. doi: 10.1161/01.str.0000058493.94875.9f. PubMed: PMID12624295.

Share this page: